These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 27131775)

  • 1. What Determines How Much Your Patient Pays for Their Medication in the United States?
    Novack GD
    Am J Ophthalmol; 2016 Jul; 167():48-51. PubMed ID: 27131775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Web-based survey to assess the perceptions of managed care organization representatives on use of copay subsidy coupons for prescription drugs.
    Nemlekar P; Shepherd M; Lawson K; Rush S
    J Manag Care Pharm; 2013 Oct; 19(8):602-8. PubMed ID: 24074006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
    Tseng CW; Brook RH; Keeler E; Mangione CM
    JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
    Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
    J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
    Academy of Managed Care Pharmacy
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.
    Fairman KA; Motheral BR; Henderson RR
    Clin Ther; 2003 Dec; 25(12):3147-61; discussion 3144-6. PubMed ID: 14749153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization and Costs of Compounded Medications for Commercially Insured Patients, 2012-2013.
    McPherson T; Fontane P; Iyengar R; Henderson R
    J Manag Care Spec Pharm; 2016 Feb; 22(2):172-81. PubMed ID: 27015256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of Copayment Offsets for Prescription Drugs in the United States.
    Sen AP; Kang SY; Rashidi E; Ganguli D; Anderson G; Alexander GC
    JAMA Intern Med; 2021 Jun; 181(6):758-764. PubMed ID: 33779680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization.
    Motheral B; Fairman KA
    Med Care; 2001 Dec; 39(12):1293-304. PubMed ID: 11717571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicians' opinions about responsibility for patient out-of-pocket costs and formulary prescribing in two Midwestern states.
    Khan S; Sylvester R; Scott D; Pitts B
    J Manag Care Pharm; 2008 Oct; 14(8):780-9. PubMed ID: 18983207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential impact of pharmaceutical industry rebates on medication adherence.
    Zullig LL; Granger BB; Vilme H; Oakes MM; Bosworth HB
    Am J Manag Care; 2019 May; 25(5):e135-e137. PubMed ID: 31120709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir initial therapy abandonment and manufacturer coupons in a commercially insured population.
    Karmarkar TD; Starner CI; Qiu Y; Tiberg K; Gleason PP
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP191-7. PubMed ID: 27266948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing prescription drug costs.
    Sica JM
    Empl Benefits J; 2001 Mar; 26(1):35-40. PubMed ID: 11272515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to pharmacy benefit management and the impact of consumer cost sharing.
    Olson BM
    Clin Ther; 2003 Jan; 25(1):250-72. PubMed ID: 12637125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.